A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

Inclusion Criteria: * Clinical diagnosis of osteoarthritis of the knee or hip that requires treatment * American Rheumatism Association (ARA) functional Class I, II or III * Receiving a stable dose of a traditional non-steroidal anti-inflammatory drug (NSAID), a Cox-2 selective inhibitor (other than etoricoxib, e.g. celecoxib), opioid therapy or tramadol to treat their osteoarthritis-related pain for at least 2 weeks and willing to maintain treatment during baseline phase * Moderate to severe daily pain intensity on his or her current pain regimen * Excepting osteoarthritis, patient is judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests * Negative serum pregnancy test Exclusion Criteria: * Has not experienced at least 3 consecutive days of daily pain intensity \>4 on 10-point scale * Severe hepatic insufficiency * Advanced renal insufficiency * Presence of gastro-intestinal ulcer disease with active bleeding or history of the same within the past 6 months or a presence or history of inflammatory bowel disease * History of gastric, biliary (including gastric bypass surgery), or small intestinal surgery that results in clinical malabsorption * Receiving or will likely require treatment with ≥14 consecutive days or repeated courses of pharmacologic doses of corticosteroids * Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease including a history of stroke, myocardial infarction or transient ischemic attack, and recent revascularization procedures * Any other contraindications mentioned in the approved study drug European Union (EU) Summary of Product Characteristics (SmPC) * Therapy with glucosamine and/or chondroitin sulfate for \<6 months prior to study start.